Business · Companies · 1 hr ago
Samsung Biologics raises 2.665 trillion won in share sale
Samsung Biologics raised 2.665 trillion won through a share sale in South Korea.
Investors placed orders for more than 11.4 trillion won of the shares left after existing shareholders and employees had a chance to buy.
That demand meant the remaining shares were oversubscribed 135.6 times.
A rights issue lets a company raise money by issuing new shares, and Samsung Biologics plans to use the funds to speed up its planned acquisition of PolyPeptide Group.
The Swiss company makes peptide medicines, including products linked to the growing market for GLP-1 weight-loss treatments.
The share sale’s remaining steps are due on Nov.
17 for payment and Nov.
30 for listing.
Samsung Biologics raised 2.665 trillion won through a share sale that drew 11.44 trillion won in subscription deposits.
The public offering drew subscriptions for about 9.75 million shares against 71,854 shares available, a subscription rate of 135.6 to 1.
The company issued 2.27 million ordinary shares in the rights offering.
Samsung Biologics plans to use the funds to advance its acquisition of Swiss peptide contract developer and manufacturer PolyPeptide Group.
The offering’s payment is due on November 17, with the new shares scheduled to list on November 30.
- Who
- Samsung Biologics.
- What
- It raised 2.665 trillion won through a rights offering that included a public offering.
- When
- The public subscription took place on November 12 and 13, and the company announced the result on November 16, 2026.
- Where
- Not stated.
- Why
- The company plans to use the funds to advance its acquisition of Swiss peptide contract developer and manufacturer PolyPeptide Group.
This story does not have two clearly opposing sides.
The public subscription for shares left after subscriptions by existing shareholders and the employee stock ownership association took place.
Samsung Biologics announced that the share sale had raised 2.665 trillion won.
Payment for the share offering is due.
The new shares are scheduled to list.
- Funds raised
- 2.665 trillion won
- Public-offering subscription deposits
- 11.4407 trillion won
- Subscription rate
- 135.6 to 1
- Shares issued
- 2.27 million ordinary shares
- Planned acquisition
- PolyPeptide Group, a Swiss peptide contract developer and manufacturer
1 source
What people are saying
The largest ever among rights offerings that included a public offering